


Mark Lambrecht (SAS)

Peter Van Reusel (Business & Decision Life Sciences)







### Agenda

Introduction SAS Drug Development

**CDmation** 


**Use Cases** 

Reports in SAS Drug Development





#### **Clinical Trials Process**







# SAS and the Next Generation of Clinical Research

## Collaboration and Access

- Accessanywhere web interface
- User, team and role-based access
- Messaging and alerts
- Shared libraries

## Confidence and Control

- Compliant, regulated environment
- Activity traceability
- Transparency
- Reproducibility

#### Process Improvements

- Workflow support and process orchestration
- eProtocol, EDC and eSubmission integration
- Automated work assignments and transitions

#### Advanced Analytics

- Scientific analytics
- Business analytics
- Data exploration
- Data visualization





# Clinical Data Analysis and Reporting Business Needs



# Needs for a metadata management solution versus SDD

#### OK

- Robust platform to cover other parts of clinical data management and statistics
- Need to store data
- Need to have several workflows
- Capability to execute SAS code
- Traceability, security and audit
- Reporting capabilities

#### But...

- UI for granular data standards management
- Study specification process
- Study validation process


















# Come to the rescue... Robust SDD Application Programming Interface


SDD 4.X JAVA API OVERVIEW








#### SDD = extensible and modular











### Agenda

Introduction SAS Drug Development

**CDmation** 

**Use Cases** 

Reports in SAS Drug Development





#### **CDmation**


An integrated solution with six components:









## **CDmation's playing field**




#### **Functionalities**




#### **Functionalities**



#### **Functionalities**



### **CDmation Roadmap**



### Agenda

Introduction SAS Drug Development

**CDmation** 

**Use Cases** 

Reports in SAS Drug Development





### **Use Case 1 – Study Specification**

#### Study Specification and Metadata Repository


- Pick and Select study creation
- Creation of Trial Design specifications
- Defines all study specifications in a controlled manner
- Allows generating a study metadata repository for comparison reporting within and across studies
- Generates a define.xml upfront
- Ensures CDISC compliant study specifications for your CRO early in the process, maintains data consistency, facilitates submission activities and increases overall quality and reduces rework





### **Data Standards Library**


- The Data Standards Library contains :
  - Data Collection Modules:
    - using CDASH metadata
    - with clustered SDTM metadata
    - annotated for CDASH
    - annotated for SDTM
    - front end edit checks
    - CRF completion Instructions
  - Metadata Definitions :
    - SDTM Standards
    - Therapeutic Area Standards








#### **Data Collection Modules - CDASH**



Life Sciences


#### **Data Collection Modules - SDTM**








## **Study Specification**







#### Define.xml







### **Use Case 2 – Study Validation**


#### **Study Validation**

- Comparison reports against specifications
- Validation performed on structural and content level
- Output in Excel spreadsheet, HTML and PDF report
- Output also stored in the Feedback Tracker
- Ensures improved vendor communication, CDISC compliance and readiness, increases quality, reduces rework.





#### Select checks => Create Job







### Run job => Review issues




#### Reported Exception Record Identifiers Exception Attributes

KID ERRORMSG	SEVERIT	Y STUDYID	DOMAIN	<b>■ USUBJID ■ KEY1CD</b>	KEY1 VAR1CD	VAR1	VAR2CD	VAR2
The STANDARD UNIT is not consistent per TEST or								
1002 EXAMINATION.	High	1000-0000	LB		LBTESTCD	LIPASE	LBSTRESU	%
The STANDARD UNIT is not consistent per TEST or								
1002 EXAMINATION.	High	1000-0000	LB		LBTESTCD	LIPASE	LBSTRESU	mmol/L
The STANDARD UNIT is not consistent per TEST or								
1002 EXAMINATION.	High	1000-0000	LB		LBTESTCD	ALKP	LBSTRESU	U
The STANDARD UNIT is not consistent per TEST or								
1002 EXAMINATION.	High	1000-0000	LB		LBTESTCD	ALKP	LBSTRESU	U/L
The STANDARD UNIT is not consistent per TEST or								
1002 EXAMINATION.	High	1000-0000	LB		LBTESTCD	LIPASE	LBSTRESU	IU/L
START DATE/TIME OF OBSERVATION falls after the END								
1005 DATE/TIME OF OBSERVATION.	High	1000-0000	AE	1000-0000-00019 AESEQ	1 AESTDTC	1998-12-01T17:00	AEENDTC	1998-12-01T16:3
START DATE/TIME OF OBSERVATION falls after the END								
1005 DATE/TIME OF OBSERVATION.	High	1000-0000	AE	1000-0000-00037 AESEQ	1 AESTDTC	1998-12-15T07:40	AEENDTC	1998-11-25T08:0
START DATE/TIME OF OBSERVATION falls after the END								
1005 DATE/TIME OF OBSERVATION.	High	1000-0000	SE	1000-0000-00004 SESEQ	2 SESTDTC	1998-11-17T08:06:00	SEENDTC	1998-11-17T07:0
START DATE/TIME OF OBSERVATION falls after the END								
1005 DATE/TIME OF OBSERVATION.	High	1000-0000	SE	1000-0000-00009 SESEQ	2 SESTDTC	1998-11-24T08:00:00	SEENDTC	1997-11-24T08:0
START DATE/TIME OF OBSERVATION falls after the END								
1005 DATE/TIME OF OBSERVATION.	High	1000-0000	SV	1000-0000-00022	SVSTDTC	1998-12-03	SVENDTC	1998-12-02
START DATE/TIME OF OBSERVATION falls after the END								
1005 DATE/TIME OF OBSERVATION.	High	1000-0000	SV	1000-0000-00010	SVSTDTC	1998-11-24	SVENDTC	1998-11-22
START DATE/TIME OF OBSERVATION falls after the END								
1005 DATE/TIME OF OBSERVATION.	High	1000-0000	SV	1000-0000-00014	SVSTDTC	1998-11-16	SVENDTC	1998-10-16
START DATE/TIME OF OBSERVATION falls after the END								
1005 DATE/TIME OF OBSERVATION.	High	1000-0000	SV	1000-0000-00035	SVSTDTC	1998-12-17	SVENDTC	1997-12-17
The LENGTH of theTEST variable is more than 40						ERY. MEAN CORPUSCULAR HB		
1007 characters.	High	1000-0000	LB	1000-0000-00001 LBSEQ	35 LBTEST	CONCENTRATION MEAS	LENGTH	
The LENGTH of theTEST variable is more than 40						PARTIAL THROMBOPLASTINE TIME		
1007 characters.	High	1000-0000		1000-0000-00030 LBSEQ	54 LBTEST	MEASUREMENTS	LENGTH	
1008 TheTESTCD starts with a number.	High	1000-0000	LB	1000-0000-00001 LBSEQ	3 LBTESTCD	2AMYL		
An ORIGINAL RESULT is completed but the STANDARD							· COTOCO	
1009 RESULT (CHARACTERISTIC) is missing.	High	1000-0000	E	1000-0000-00006 IESEQ	1 IEORRES	N	IESTRESC	
An ORIGINAL RESULT is completed but the STANDARD	LEste	4000 0000		4000 0000 00004 00005	4 00000	8.6	COCTOCC	
1009 RESULT (CHARACTERISTIC) is missing.	High	1000-0000	SC	1000-0000-00031 SCSEQ	1 SCORRES	R-K	SCSTRESC	
An ORIGINAL RESULT is completed but the STANDARD		4000 0000		1000 0000 00011 00000	4.0000000	1415	00070500	
1009 RESULT (CHARACTERISTIC) is missing.	High	1000-0000	SC	1000-0000-00014 SCSEQ	1 SCORRES	W-B	SCSTRESC	
An ORIGINAL RESULT is completed but the STANDARD								
1009 RESULT (CHARACTERISTIC) is missing.	High	1000-0000	SC	1000-0000-00022 SCSEQ	1 SCORRES	M-U	SCSTRESC	





#### Manage Issues



### Agenda

Introduction SAS Drug Development

**CDmation** 


**Use Cases** 

Reports in SAS Drug Development






#### **REPORTING** possibilities








# Reporting capability





Data Standards Library Comparison Implementation Guides Completion Guides Trial summary-based search reports Metrics reports Study metadata comparison across study versions Study metadata comparison across projects Define.xml Export of trial design datasets Study metadata-based search reports





# Reporting capability (1)

Data Standards Library Comparison







## Reporting capability (2)

#### Implementation Guides



This section describes for all variables the following

- V ariable name
- ☐ Variable label
- □ Variable type (numeric or character) and length
- ☐ Controlled terminology used
- Origin (unique origin or combination of the following: CRF, eDT, derived, assigned and protocol)
- Role (identifier, topic, timing, grouping qualifier, result qualifier, synonym qualifier, record qualifier or variable qualifier)
- ☐ Core (required= req, expected = exp, permissible= perm)
- Comment (relevant information that further clarifies the variable)

Special purpose domains **ABBREVIATIO** LABEL LENGTH NAME NAME NAME NAME DATASET NAME Study Identifier ΔF STUDYID 40 Reg Identifier text ΑE STUDYID Study Identifier 40 Reg Identifier text ΑE 40 Reg STUDYID Study Identifier Identifier text ΑE STUDYID Study Identifier Identifier





11

# Reporting capability (3)

Study Metadata Comparison

- 2 different statuses:
  - Ok : no metadata conflict
  - Difference: difference in metadata value between studies

	Status D		Dataset	Label	A1000_0000	A1000_0001		A1000_00	02
	Ok	AE		Adverse Events	X	X		X	
S	tatus	Refere	nce Comput	ational algorithm		A1000_0000		A1000_0001	A1000_0002
Dif	ference	DM.AG	E Equal to OBTAIN	(DS.DSSTDTC-DM.BRTHDTC)/365.25 where DSTERM ED'	X				
Dif	ference	DM.AG	AGE Equals to (DS.DSSTDTC-DM.BRTHDTC)/365.25 where DSTERM = 'INFORMED CONSENT OBTAINED'						X
	Difference DM		DM	Demographic X		X			
	Ok	Ok DS		Disposition	X	X		X	






# SAS Drug Development – integration with CDMation

- SAS Drug Development = open extensible platform
- Integration
  - 1. User access and security model
    - Re-use system metadata, login session of SDD
    - Integrated user experience (including single sign-on)
    - Integrated user roles & privileges
  - 2. Audit trail and permission reports
    - Access from SDD-executed SAS code to all metadata from SDD and CDMation (audit trail, permissions)
  - 3. Metadata validation flow across all parts
    - Jobs (SAS programs) running in controlled execution environment with complete access to CDMation standards and study metadata
    - One integrated repository for jobs, documents and other output













Mark Lambrecht | Principal Consultant • Health and Life Sciences Global Practice • SAS | T. +32 475 96 06 58 | mark.lambrecht@sas.com Peter Van Reusel | COO Businesss & Decision Life Sciences | T. +32 476 54 59 17 | peter.vanreusel@businesssdecision.com

#### **Business & Decision Life Sciences**

Sint-Lambertusstraat - 141 rue Saint-Lambert

B-1200 Brussels

T: +32 2 774 11 00

F: +32 2 774 11 99

lifesciences@businessdecision.com http://www.businessdecision-lifesciences.com/

#### SAS Institute Inc.

100 SAS Campus Drive Cary, NC 27513-2414, USA http://www.sas.com